Figure 8
From: Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells
MDA/RLN2 transfectants show reduced tumour growth in vivo. 2 × 107 cells/ml of the MDA/EGFP plasmid control transfectant and two of the MDA/RLN2 transfectants, MDA/RLN2-19 and MDA/RLN2-23, were injected subcutaneously in nude mice and the tumour growth rate (n = 10 tumours for each cell clone) was determined after 60 days of growth. All MDA/RLN2 xenografts showed slower tumour growth and smaller tumour sizes compared with the MDA/EGFP xenografts. Data are presented as mean ± SEM of tumour volume (mm3). A two-way ANOVA analysis was performed to determine statistical significance with p < 0.005 considered significant (**).